Gene editing · Gene editing: angiotensinogen (AGT) · developed by CRISPR Therapeutics
CTX340 is an in vivo gene editing therapy that uses CRISPR-Cas9 to target and disrupt the human angiotensinogen (AGT) gene in the liver. It is being studied in hypertension.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07758634 | Phase 1/2 | Hypertension | Recruiting | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hypertension
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →